Drugs / RBP-8000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01846481 | Apr → Jun 2013 | cocaine dependence, opiate dependence | Indivior Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-05-23 | Tonix Pharmaceuticals, Inc. | Regulatory Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication tonixpharma.com ↗
TNX-1300 is designated as a breakthrough therapy by the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-05-23 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication tonixpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBP-8000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01846481 ↗ |
| Route | Intravenous | “RBP-8000 100 mg administered in the vein on either study day 3 or 6” NCT01846481 ↗ |